ArticleBMC cancer2021
Clinically significant genomic alterations in the Chinese and Western patients with intrahepatic cholangiocarcinoma.
Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Global patterns of mutational profiles in biliary tract cancer.Journal of hepatology · 2026Article
- CBC3T-3: a novel patient-derived cisplatin-resistant distal cholangiocarcinoma cell line harboring multiple TP53 missense mutations.Human cell · 2026Article
- Actionable genomic landscape of biliary tract cancer in the Indian population.The oncologist · 2026Article
- LINC00519 promotes the progression of cholangiocarcinoma through regulating the axis of miR-876-3p/GATA1.Discover oncology · 2025Article
- Article
- Precision medicine for advanced biliary tract cancer in China: current status and future perspectives.Frontiers of medicine · 2025Review
- Clinical Implications and Novel Insights into Adolescent Primary Liver Cancer: A Nightmare for Adolescents?Journal of hepatocellular carcinoma · 2025Article
- The Landscape and Therapeutic Targeting ofCurrent issues in molecular biology · 2023Review
- Tumor grade-associated genomic mutations in Chinese patients with non-small cell lung cancer.Frontiers in oncology · 2023Article
- Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress.Current oncology (Toronto, Ont.) · 2022Article
- Molecular Profile and Prognostic Value ofJournal of personalized medicine · 2022Article
- Gene Mutational Clusters in the Tumors of Colorectal Cancer Patients With a Family History of Cancer.Frontiers in oncology · 2022Article
- Gene Mutations Associated With Clinical Characteristics in the Tumors of Patients With Breast Cancer.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundThe goal of this study is to disclose the clinically significant genomic alterations in the Chinese and Western patients with intrahepatic cholangiocarcinoma.
methodsA total of 86 Chinese patients were enrolled in this study. A panel of 579 pan-cancer genes was sequenced for the qualified samples from these patients. Driver genes, actionability, and tumor mutational burden were inferred and compared to a cohort of Western patients.
resultsTotally, 36 and 12 driver genes were identified in the Chinese and Western cohorts, respectively. Of them, seven driver genes (IDH1, KRAS, TP53, BAP1, PBRM1, ARID1A, and NRAS) were shared by the two cohorts. Four driver genes (SPTA1, ARID2, TP53, and GATA1) were found significantly correlated with the tumor mutational burden. For both cohorts, half of the patients had actionable mutations. The two cohorts shared the most actionable genes but differed much in their frequency. Though KRAS mutations were at the first and second actionable rank respectively for the Chinese and Western populations, they were still at a relatively low level of actionable evidence.
conclusionsThe study on the clinical significance of genomic alterations directs the future development of precision medicine for intrahepatic cholangiocarcinoma treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.